X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Reliance Life Sciences has been granted authorization to undertake a phase 1 clinical study of its recombinant protein-based Covid-19 vaccine candidate by the Central Drugs Standard Control Organisation (CDSCOS)'s Expert Committee (SEC).
Lead Product(s): Recombinant Protein-based Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2021
Details:
The aim of phase I clinical trials is to obtain reliable information on safety, tolerability, pharmacokinetics (PK), and mechanism of action of the recombinant protein based covid-19 vaccine with the objective of determining the maximum tolerated dose (MTD).
Lead Product(s): Recombinant Protein Based Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2021
Details:
The Agreement grants an exclusive right to Medicure to market and sell the Product in the United States of America, Canada and the European Union.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Medicure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
